These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8937965)

  • 1. Cefepime activity against Pseudomonas aeruginosa: evaluation of Etest and two disc diffusion methods.
    Stes P; Goossens H
    J Antimicrob Chemother; 1996 Oct; 38(4):707-11. PubMed ID: 8937965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1989 Oct; 8(10):917-9. PubMed ID: 2512141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the activity of two broad-spectrum cephalosporins tested against 2,299 strains of Pseudomonas aeruginosa isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.
    Ramphal R; Hoban DJ; Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2000 Feb; 36(2):125-9. PubMed ID: 10705055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Christenson JC; Korgenski EK; Daly JA
    J Antimicrob Chemother; 2000 Jun; 45(6):899-901. PubMed ID: 10837448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of four methods for the determination of the susceptibility of 47 strains of Pseudomonas aeruginosa to ceftazidime and cefepime: influence of the choice of interpretative criteria].
    Boucaud-Maître Y; Thoinet S
    Pathol Biol (Paris); 1996 May; 44(5):363-6. PubMed ID: 8758477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
    Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftazidime, cefepime and imipenem on 1,005 Pseudomonas aeruginosa clinical isolates either susceptible or resistant to beta-lactams.
    Bonfiglio G; Marchetti F
    Chemotherapy; 2000; 46(4):229-34. PubMed ID: 10859428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
    Tumah H
    Chemotherapy; 2005 May; 51(2-3):80-5. PubMed ID: 15870501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of pseudomonas aeruginosa to cefepime versus ceftazidime in patients with cystic fibrosis.
    Robinson CA; Kuhn RJ; Craigmyle J; Anstead MI; Kanga JE
    Pharmacotherapy; 2001 Nov; 21(11):1320-4. PubMed ID: 11714203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.
    Aubert D; Poirel L; Chevalier J; Leotard S; Pages JM; Nordmann P
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1615-20. PubMed ID: 11353602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
    Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
    J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens.
    Tumah HN
    Pharmazie; 2004 Nov; 59(11):854-8. PubMed ID: 15587586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the Vitek system to accurately test the susceptibility of Pseudomonas aeruginosa clinical isolates against cefepime.
    Jones RN; Biedenbach DJ; Marshall SA; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):107-10. PubMed ID: 9823533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of cefepime, ceftazidime, and ceftizoxime against mutants of Enterobacteriaceae and Pseudomonas aeruginosa derepressed for class I beta-lactamase.
    Knapp CC; Washington JA
    J Antimicrob Chemother; 1989 Dec; 24(6):1011-2. PubMed ID: 2516083
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
    Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime.
    Fung-Tomc J; Huczko E; Pearce M; Kessler RE
    Antimicrob Agents Chemother; 1988 Sep; 32(9):1443-5. PubMed ID: 3143306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.